# A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)

> **NCT02004522** · PHASE3 · COMPLETED · sponsor: **SecuraBio** · enrollment: 319 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Duvelisib
- **DRUG:** Ofatumumab

## Key facts

- **NCT ID:** NCT02004522
- **Lead sponsor:** SecuraBio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2017-05-19
- **Final completion:** 2021-06
- **Target enrollment:** 319 (ACTUAL)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02004522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02004522, "A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02004522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*